Status:
COMPLETED
Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Lead Sponsor:
Kissei Pharmaceutical Co., Ltd.
Conditions:
Spinocerebellar Degeneration
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
To evaluate the efficacy, safety and pharmacokinetics profile of KPS-0373 in patients with SCD
Eligibility Criteria
Inclusion
- SCD with mild to moderate ataxia
Exclusion
- Patients with secondary ataxia
- Patients with clinically significant hepatic, renal, or cardiovascular dysfunction
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00863538
Last Update
February 3 2010
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Japan
Hokkaido Region, Japan
2
Japan
Kansai Region, Japan
3
Japan
Kanto Region, Japan